Reimagining Public Sector Analytics
Home News Enterprise IT OmniComm completes acquisition of Algorics, will get AI boost

OmniComm completes acquisition of Algorics, will get AI boost

OmniComm Completes Asset Acquisition of Algorics

OmniComm Completes acquisition of Algorics. (Photo: Agency)

technology firm has completed the acquisition of certain assets and assumed certain liabilities of , a provider of clinical solutions and software, said a statement. According to , this acquisition significantly enhances its product portfolio with advanced data analytics capabilities, specialized algorithms and artificial intelligence, machine learning, developed by Algorics.

Acuity is a system-agnostic platform that provides powerful and flexible data aggregation, and visualization that drive actionable knowledge in real time. Acuity improves productivity and minimizes risk in clinical research by providing a clear vision of clinical and operational data. Acuity will provide enhanced real-time and cross-study reporting capabilities for OmniComm's TrialMaster and TrialOne electronic data capture (EDC) product lines.

“This is definitely a very good acquisition for both OmniComm and Algorics,” said Nithiya Ananthakrishnan, who was the CEO and founder of Algorics. “By joining with OmniComm, we will accelerate our goal of becoming the best-in-class solution for risk-based monitoring and clinical data analytics. We look forward to bringing additional competitive advantages to OmniComm's customers by delivering end-to-end RBM solutions and specialized data analytics expertise.”

Now, Ananthakrishnan will assume the role of senior vice president of Data Sciences at OmniComm, reporting to Stephen Johnson, president and CEO of OmniComm.

“Adding this RBM and analytics platform to our existing product lines fills a strong need for our clients,” Johnson said. “Due to a common technology stack, the Acuity platform perfectly integrates with our TrialMaster and TrialOne solutions. We are excited to share our newest technology with our clients to help them derive more power from their clinical research data.”

Exit mobile version